Stephen Dean Sharp & David John Hughes v GE Healthcare Bio-Sciences AB

Link copied
Case Copied 34 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Stephen Dean Sharp & David John Hughes v GE Healthcare Bio-Sciences AB [2014] APO 10

Patent Application:                   2005317279

Title:Purification of immunoglobulins

Patent Applicant:  GE Healthcare Bio-Sciences AB

Opponent:  Stephen Dean Sharp & David John Hughes

Delegate:  Dr B. Akhurst

Decision Date:  19 February 2014

Hearing Date:  28 November 2013, in Canberra

Catchwords:  PATENTS - section 59 opposition - no evidence in answer to the opposition or submissions from the applicant - inventive step - claims found to lack an inventive step in light of a prior art document cited in the application - manner of manufacture - not established that the claimed combination is obvious on the face of the specification - useful - on a proper construction the claimed invention is useful - clarity - the claims provide a workable standard suitable to the intended use - lack of clarity not established - fair basis -the claims need not be limited to the preferred embodiments - lack of fair basis not established.

Representation:  Patent applicant: Did not attend the hearing

Opponent: Dr Peter Brown, Griffith Hack, Sydney

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2005317279

Title:Purification of immunoglobulins

Patent Applicant:  GE Healthcare Bio-Sciences AB

Date of Decision:  19 February 2014

DECISION

The opposition is successful.  The invention of claims 1-2, 4-5 and 7-17 lacks an inventive step.

I believe it is possible to overcome the deficiencies I have identified by amendment of the specification.  I therefore allow GE Healthcare Bio-Sciences AB two (2) months from the date of this decision to propose such amendments.

Costs are awarded according to Schedule 8 against GE Healthcare Bio-Sciences AB.

REASONS FOR DECISION

Background

  1. Patent application 2005317279 was filed by GE Healthcare Bio-Sciences AB via the PCT on 12 December 2005 claiming priority from application SE 0403057-3 filed on 14 December 2004 and US 60/638,316 filed on 22 December 2004.  The application entered national phase on 30 May 2007 and after examination was advertised as accepted on 24 February 2011. 

  2. Stephen Dean Sharp & David John Hughes filed a notice of opposition to grant of a patent on 24 May 2011 and served the statement of grounds and particulars on 24 August 2011.   Evidence in support was completed on 24 April 2013 and consisted of a declaration by Robert L. Raison (the RLR declaration) with exhibits RLR-1 to RLR-11, and declarations by librarians Ngaine Ann Pettit-Young and Fiona Grigg.

  3. No evidence was filed in answer to the opposition.  On 30 August 2013 the applicant advised that it would not attend the hearing and that it wished the opposition to be determined on the basis of the evidence already before the Patent Office.  The opponent was heard in Canberra on 28 November 2013.

    Grounds of opposition

  4. At the hearing, the grounds of opposition pressed by the opponent were manner of manufacture, inventive step, usefulness, clarity and fair basis. 

    Onus of Proof

  5. The request for examination in this case was filed on 15 August 2007.  Therefore, the substantive amendments to…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Stephen Dean Sharp & David John Hughes v GE Healthcare Bio-S... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] APO 10
Decision Date

CaseChat Overview and Summary

In the case of Stephen Dean Sharp & David John Hughes v GE Healthcare Bio-Sciences AB, the Australian Patent Office reviewed an opposition to a patent application for the purification of immunoglobulins. The application was filed by GE Healthcare Bio-Sciences AB, with a priority date of December 14, 2004. Stephen Dean Sharp and David John Hughes opposed the grant of the patent on various grounds, including lack of inventive step, usefulness, clarity, and fair basis. The case was heard on November 28, 2013, and a decision was rendered on February 19, 2014.

The key legal issues the court had to decide included whether the patent application met the criteria for inventive step, usefulness, clarity, and fair basis as required by the Australian Patents Act. The court examined the prior art and the specification to determine if the claimed invention was novel and non-obvious, useful, clearly defined, and fairly based on the disclosed matter.

The court found that claims 1-2, 4-5, and 7-17 of the patent application lacked an inventive step as they could be derived from the prior art, specifically US Patent US'990. The court determined that the person skilled in the art would have been directly led to the claimed invention as a matter of routine without any inventive effort. The court also found that the claimed invention was useful, clear, and fairly based on the specification. The court allowed GE Healthcare Bio-Sciences AB two months to amend the specification to overcome the identified deficiencies. Costs were awarded to the opponents according to Schedule 8.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.